At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 282 enrolled
Drug / intervention
BBI608 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma
In Brief
A Phase 3 clinical trial evaluating BBI608, Placebo, and 1 other intervention for Colorectal Carcinoma. Completed, enrolled 282 participants across 63 sites in 3 countries.
Detailed Summary
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, or better to receive no further treatment for colon or rectal cancer. To do this, half of the patients in this study will get BBI608 and the other half will receive a placebo (a substance that is designed not to do anything).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Carcinoma
CountriesAustralia, Canada, Japan
CollaboratorsSumitomo Pharma America, Inc.
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionMay 2016
Study CompletionMay 2016
TodayJul 2026
First PostedApr 12, 2013
Enrollment StartMay 10, 2013
Primary CompletionMay 7, 2016
Study CompletionMay 16, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 13.2 years ago
Interventions
BBI608drug
Placebodrug
Best Supportive Careother